Phosphatidylinositide-3-Kinase Inhibitors: Addressing Questions of Isoform Selectivity and Pharmacodynamic/Predictive Biomarkers in Early Clinical Trials

被引：24

作者：

Clarke, Paul A. ^{[1
]}

Workman, Paul ^{[1
]}

机构：

[1] Inst Canc Res, Haddow Labs, Sutton, Surrey, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 03期

关键词：

CLASS-I; HUMAN CANCER; POTENT; DISCOVERY; MUTATIONS; PATHWAY;

D O I：

10.1200/JCO.2011.38.7167

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：331 / 333

页数：3

共 14 条

[1] WORTMANNIN IS A POTENT PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR - THE ROLE OF PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE IN NEUTROPHIL RESPONSES
ARCARO, A
WYMANN, MP
[J]. BIOCHEMICAL JOURNAL, 1993, 296 : 297 - 301
[2] Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Bendell, Johanna C.
Rodon, Jordi
Burris, Howard A.
de Jonge, Maja
Verweij, Jaap
Birle, Diana
Demanse, David
De Buck, Stefan S.
Ru, Qinhua C.
Peters, Malte
Goldbrunner, Michael
Baselga, Jose
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (03) : 282 - 290
[3] Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer
Burger, Matthew T.
Pecchi, Sabina
Wagman, Allan
Ni, Zhi-Jie
Knapp, Mark
Hendrickson, Thomas
Atallah, Gordana
Pfister, Keith
Zhang, Yanchen
Bartulis, Sarah
Frazier, Kelly
Ng, Simon
Smith, Aaron
Verhagen, Joelle
Haznedar, Joshua
Huh, Kay
Iwanowicz, Ed
Xin, Xiaohua
Menezes, Daniel
Merritt, Hanne
Lee, Isabelle
Wiesmann, Marion
Kaufman, Susan
Crawford, Kenneth
Chin, Michael
Bussiere, Dirksen
Shoemaker, Kevin
Zaror, Isabel
Maira, Sauveur-Michel
Voliva, Charles F.
[J]. ACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (10): : 774 - 779
[4] COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer
Forbes, Simon A.
Tang, Gurpreet
Bindal, Nidhi
Bamford, Sally
Dawson, Elisabeth
Cole, Charlotte
Kok, Chai Yin
Jia, Mingming
Ewing, Rebecca
Menzies, Andrew
Teague, Jon W.
Stratton, Michael R.
Futreal, P. Andrew
[J]. NUCLEIC ACIDS RESEARCH, 2010, 38 : D652 - D657
[5] Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, Pixu
Cheng, Hailing
Roberts, Thomas M.
Zhao, Jean J.
[J]. NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (08) : 627 - 644
[6] Maira M, 2010, AM ASS CANC RES ANN
[7] Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
Raynaud, Florence I.
Eccles, Suzanne A.
Patel, Sonal
Alix, Sonia
Box, Gary
Chuckowree, Irina
Folkes, Adrian
Gowan, Sharon
Brandon, Alexis De Haven
Di Stefano, Francesca
Hayes, Angela
Henley, Alan T.
Lensun, Letitia
Pergl-Wilson, Giles
Robson, Anthony
Saghir, Nahid
Zhyvoloup, Alexander
McDonald, Edward
Sheldrake, Peter
Shuttleworth, Stephen
Valenti, Melanie
Wan, Nan Chi
Clarke, Paul A.
Workman, Paul
[J]. MOLECULAR CANCER THERAPEUTICS, 2009, 8 (07) : 1725 - 1738
[8] Shuttleworth SJ, 2011, CURR MED CHEM, V18, P2686
[9] The emerging mechanisms of isoform-specific PI3K signalling
Vanhaesebroeck, Bart
Guillermet-Guibert, Julie
Graupera, Mariona
Bilanges, Benoit
[J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2010, 11 (05) : 329 - 341
[10] AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
Vasudevan, Krishna M.
Barbie, David A.
Davies, Michael A.
Rabinovsky, Rosalia
McNear, Chontelle J.
Kim, Jessica J.
Hennessy, Bryan T.
Tseng, Hsiuyi
Pochanard, Panisa
Kim, So Young
Dunn, Ian F.
Schinzel, Anna C.
Sandy, Peter
Hoersch, Sebastian
Sheng, Qing
Gupta, Piyush B.
Boehm, Jesse S.
Reiling, Jan H.
Silver, Serena
Lu, Yiling
Stemke-Hale, Katherine
Dutta, Bhaskar
Joy, Corwin
Sahin, Aysegul A.
Gonzalez-Angulo, Ana Maria
Lluch, Ana
Rameh, Lucia E.
Jacks, Tyler
Root, David E.
Lander, Eric S.
Mills, Gordon B.
Hahn, William C.
Sellers, William R.
Garraway, Levi A.
[J]. CANCER CELL, 2009, 16 (01) : 21 - 32

← 1 2 →